Description du projet
Approches personnalisées pour de meilleurs soins de santé
Afin d’accroître la sécurité globale des patients, le projet de recherche SafePolyMed, financé par l’UE, entend développer des outils innovants pour aider les médecins et les pharmaciens à mieux définir, évaluer et gérer les interactions entre les médicaments et les gènes. L’apprentissage automatique sur de grands ensembles de données du monde réel permettra d’identifier les patients à risque; les outils de dosage de précision reposant sur des modèles contribueront à optimiser les soins; et les évaluations des résultats rapportés par les patients aideront à mesurer le succès des traitements. Les centres de gestion des médicaments serviront de plateforme aux patients et aux prestataires de soins de santé pour explorer les causes sous-jacentes des mauvais résultats des traitements et définir des plans plus personnalisés. En sensibilisant les citoyens et en leur donnant les moyens de participer à la gestion de leur thérapie, le projet vise à améliorer la communication entre les patients et les médecins, et à fournir un accès égal à des soins de santé innovants, durables et de qualité dans toute l’Europe.
Objectif
Polypharmacy, multimorbidity and genetic heterogeneity can affect drug efficacy, raise the risk for adverse drug reactions (ADRs) and increase healthcare costs. ADRs are among the leading causes of death in developed countries and a major cause of hospitalization. Drug-drug interactions (DDIs) and drug-gene interactions (DGIs) are highly interconnected and require a holistic approach to improve safety of our citizens. However, investigations on real-life drug-drug-gene interactions (DDGIs) in clinical trials are unfeasible due to combinatorial explosion, high costs and ethical concerns. Hence, significant knowledge gaps exist. Furthermore, the lack of participation in managing their conditions might be excessively demanding for polymedicated and multimorbid citizens. SafePolyMed will develop a novel and innovative framework to define, assess and manage DDGIs for physicians and individual patients resulting in education and empowerment of citizens as well as in reduced healthcare costs by improving patient safety. The main objectives of SafePolyMed are (1) development of a novel, evidence-based risk scoring system using machine learning on large real-world datasets to identify patients at risk; (2) identification and validation of patient reported outcome measures for multifactorial patient safety in collaboration with European patient organizations;
(3) development of an electronic tool to empower patients by allowing them to properly manage their therapies, check for and educate about DD(G)Is and collect their patient reported outcomes; (4) mathematical modelling of clinically relevant compounds to derive individualized dose adaptations for safe and effective dose regimens in case of DDGIs, accessible via a web-based decision support system with tailored information for either citizens or physicians and (5) validation of the developed safety tools in a ?proof-of-principle? study including representative patient cohorts from different European clinical sites.
Champ scientifique
- medical and health sciencesbasic medicinepharmacology and pharmacydrug safety
- medical and health scienceshealth sciencespersonalized medicine
- medical and health sciencesbasic medicinepharmacology and pharmacyadverse drug reactions
- natural sciencescomputer and information sciencesartificial intelligencemachine learning
- natural sciencesmathematicsapplied mathematicsmathematical model
Programme(s)
- HORIZON.2.1 - Health Main Programme
- HORIZON.2.1.6 - Health Care Systems
Régime de financement
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinateur
66123 Saarbrucken
Allemagne